STOCK TITAN
  1. Home
  2. News
  3. MTNB

Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.

The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.

Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.

Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.

Latest News:

  • A photo accompanying this announcement is available
  • Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
  • Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100
News

Matinas BioPharma Prices $10 Million Registered Direct Offering

Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (MTNB) announces a registered direct offering of common stock and warrants to institutional investors, raising approximately $10 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.86%
Tags
offering
-
News

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Rhea-AI Summary
Matinas BioPharma Holdings, Inc. reports 2023 financial results and progress on the ORALTO Phase 3 trial for MAT2203. The company aims to address severe invasive fungal infections with potential new treatment paradigms. Successful Compassionate/Expanded Use Access Program and advancements in the LNC platform demonstrate promising results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
earnings
-
News

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (MTNB) announces positive results from an in vivo study showing that oral LNC-docetaxel reduces toxicity compared to IV-docetaxel, with no weight loss observed in mice. The study highlights the potential of LNCs for targeted drug delivery in oncology applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
none
News

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Rhea-AI Summary
Matinas BioPharma announces complete clinical response in patients with invasive fusarium infection treated with MAT2203, showing promising results in difficult-to-treat cases. The oral formulation of amphotericin B demonstrated effectiveness in patients with treatment options, paving the way for the upcoming Phase 3 trial for invasive aspergillosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
none
-
News

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has successfully resolved the low selling price deficiency, regaining compliance with NYSE American's listing standards. The Company's common stock showed sustained price improvement, leading to the removal of the noncompliant status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
none
-
News

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Rhea-AI Summary
Matinas BioPharma (MTNB) provides a positive update on its Compassionate/Expanded Use Access Program with MAT2203, showing promising results in treating invasive fungal infections. Out of 19 patients enrolled, those completing treatment had complete clinical resolution, with significant improvements seen in others. MAT2203 demonstrated efficacy in patients with limited treatment options, addressing a significant medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.55%
Tags
none
News

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Rhea-AI Summary
Matinas BioPharma announces alignment with the FDA on the design of a Phase 3 trial for MAT2203 in patients with invasive aspergillosis. The trial aims to provide a step-down treatment option for adults with limited or no treatment choices, focusing on all-cause mortality and treatment-related toxicities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
clinical trial
-
News

Matinas BioPharma to Present at Biotech Showcase 2024

Rhea-AI Summary
Matinas BioPharma (NYSE American: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the Biotech Showcase 2024. The presentation will be available via webcast on the company's website. Institutional investors can schedule meetings with management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.78%
Tags
conferences
-
News

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Rhea-AI Summary
Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company (NYSE American: MTNB), reports successful oral delivery of LNC-formulated small single-strand oligonucleotides targeting key inflammatory cytokines TNFα and IL-17A in acute colitis and psoriasis models, showing significant reductions in serum TNFα levels and tissue IL-17A mRNA, with improvements in clinical disease markers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.3%
Tags
none
News

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Rhea-AI Summary
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) receives positive feedback from FDA on Phase 3 study design for MAT2203, moving closer to full alignment with FDA. Partnership discussions ongoing. Meeting with FDA planned in early 2024 to finalize Phase 3 protocol.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none

FAQ

What is the current stock price of Matinas BioPharma Holdings (MTNB)?

The current stock price of Matinas BioPharma Holdings (MTNB) is $0.545 as of December 20, 2024.

What is the market cap of Matinas BioPharma Holdings (MTNB)?

The market cap of Matinas BioPharma Holdings (MTNB) is approximately 2.9M.

What is Matinas BioPharma Holdings, Inc.?

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative anti-infective therapies for orphan indications.

What is MAT2203?

MAT2203 is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent, currently in Phase 2 clinical trials.

What is MAT2501?

MAT2501 is an orally-administered, encochleated formulation of amikacin, an antibiotic agent for acute bacterial infections, currently in Phase 1 clinical trials.

What technology does Matinas BioPharma use?

Matinas BioPharma uses proprietary lipid-crystal nano-particle cochleate technology to enhance drug safety, tolerability, and oral bioavailability.

What are the benefits of MAT2203?

MAT2203 aims to offer a safer, less toxic, and more effective oral treatment for severe fungal infections.

What types of infections does MAT2501 target?

MAT2501 targets acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections.

What is unique about Matinas BioPharma's approach?

Matinas BioPharma's approach is unique due to its use of lipid-crystal nano-particle cochleate technology, which improves the safety and effectiveness of existing drugs.

Who can I contact for investor relations inquiries?

For investor relations inquiries, contact Jody Cain at LHA Investor Relations via email at Jcain@lhai.com or by phone at 310-691-7100.

What is the status of MAT2203 clinical trials?

MAT2203 is currently in Phase 2 clinical trials.

What recent achievements has Matinas BioPharma reported?

Recent achievements include studies demonstrating prolonged survival and reduced fungal burden in a neutropenic mouse model.

Stock MTNB logo
Matinas BioPharma Holdings, Inc.

NYSE:MTNB

MTNB Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MTNB Stock Data

2.88M
4.96M
2.49%
26.08%
0.65%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BEDMINSTER